Lundbeck CEO on most controversial drug approval in recent memory: Will bring new innovation

The FDA's approval of Biogen's aducanumab against Alzheimer's disease could lead to new and decisive breakthroughs in treatments of the disease, predicts Lundbeck CEO Deborah Dunsire.

Photo: Gregers Tycho/ERH

The most controversial drug approval by far in recent memory is met with support from pharmaceutical company Lundbeck's chief executive, Deborah Dunsire.

Unlike a range of experts, she perfectly understands the US Food and Drug Administration's approval of the drug Aduhelm (aducanumab) for treating the dreaded and deadly neurodegenerative disease Alzheimer's.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs